Background: The aim of this study was to evaluate the pharmacokinetics of lamivudine (3TC), stavudine (d4T) and nevirapine (NVP) in HIV-infected Malawian children receiving quartered tablet multiples of Triomune 40™ (generic tablet [GT]) compared with individual generic liquid (GL) and trade liquid (TL). Methods: This was a prospective randomized three-way crossover study. Patients (8-<12 kg, 18-<22 kg or 28-<32 kg body weight) taking Triomune 40™ were recruited and randomized to receive GT twice daily (one-quarter, one-half or three-quarter tablets using Malawi treatment guidelines), GL twice daily (in the equivalent dose of GT) or TL twice daily (dosed using weight and age from US Department of Health and Human Services paediatric treatment guidelines). After 10 days of one formulation, 6-h pharmacokinetic sampling was performed, and patients were crossed over to subsequent formulations. Baseline concentration (C 0 h ), area under the curve (AUC) 0-6 h , maximum plasma concentration (C max ) and time to C max were generated for each antiretroviral treatment. Results: A total of 7 males and 11 females (6 in each GT dosing group) with a median (range) age of 7.2 years (1.3-13.6), weight of 19 kg (9.0-30.5) and height of 109 cm (75-132) were recruited. Combining all patients, no difference in pharmacokinetics was noted among the formulations for all drugs. However, patients in the onequarter GT dosing group (8-<12 kg) had lower 3TC exposures than with the GL or TL (3TC AUC 0-6 h 1,102, 1,720 and 2,060 h•ng/ml, respectively; P<0.005) and had more subtherapeutic NVP C 0 h (10 of 13 occasions versus the one-half and three-quarter tablet groups). Compared with Western paediatric cohorts, Malawians had concentrations 30-40% lower for 3TC and d4T and 50% higher for NVP. Conclusions: Quartered multiples of Triomune 40™ are appropriate for children 18-<22 kg and 28-<32 kg in weight; however, alternative formulations are suggested in children weighing 8-<12 kg.
Original article

Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIVinfected Malawian children
Introduction of this generic combination is substantially lower (US $11 per month) than trade products (US $170 per month). This product is used as whole tablets to treat adults; however, quartered multiples are being used to treat children. Although splitting unscored fixed-dose combination tablets is a suboptimal method of drug administration, by the end of December 2007, over 141,449 patients had been placed on therapy and 8% of these were children prescribed using this dosing method [3] .
Based on the established use of this product, characterizing the pharmacokinetic properties of these generic formulations is of vital importance to provide the appropriate care for these HIV-infected patients. Suboptimal exposure to antiretrovirals can lead to the emergence of resistance and treatment failure. Particularly in this setting of limited treatment options, durability of antiretrovirals is of crucial importance.
Data comparing Triomune 40™ and Triomune 30™ to individual trade products show that the content of antiretrovirals in the generic and trade products are similar [4] . Additionally, after a single dose in healthy volunteers, Triomune 40™ is bioequivalent to trade formulations [5] . However, our group recently compared the pharmacokinetics of the generic tablet (GT) to individual trade products in HIV-infected adults in Malawi [6] . Triomune 40™ did not meet the strict definition of bioequivalence as compared with individual trade products. In particular, patients taking Triomune 40™ had higher d4T maximum plasma concentrations (C max ) compared with the trade product. Additionally, Malawian adults had higher NVP concentrations than those reported in Western patients. Because generic and trade formulations might result in different antiretroviral exposures, and using quartered tablet multiples could add additional pharmacokinetic variability, we designed this study to evaluate three antiretroviral formulations in three different paediatric dosing groups.
Methods
Study setting
The study participants were recruited from both Kamuzu Central Hospital (KCH) and the Lighthouse Clinic in Lilongwe, Malawi, where >90,000 HIV-infected individuals reside. KCH is a tertiary referral hospital for the central region of Malawi and houses outpatient clinics for HIV-infected patients. The Lighthouse Clinic is on the campus of KCH and treats HIV-infected adults and children. Study visits were conducted at the University of North Carolina (UNC) Project building, which is located in proximity to and collaborates with both sites.
Study design
This was a prospective non-blinded randomized three-way crossover pharmacokinetic comparative bioavailability study of a fixed-dose combination GT, generic liquid (GL) and trade liquid (TL) formulations of d4T plus 3TC plus NVP in HIV-infected children taking Triomune 40™ (40 mg d4T plus 150 mg 3TC plus 200 mg NVP) at the time of enrolment.
Study population
The population recruited were HIV-infected children who had been taking Triomune 40™ twice daily for at least 28 days for treatment of HIV and fell into three weight categories: 8-<12 kg, 18-<22 kg or 28-<32 kg. These weights corresponded to ages of approximately 1-15 years. Children with haemoglobin <8 g/dl, aspartate or alanine aminotransferase >1× the upper limit of normal, with concomitant drug interacting medications or who were unable to return to the clinic for study visits or have blood drawn were not included in the study.
Study procedures
Human experimentation guidelines of the US Department of Health and Human Services (DHHS), the University of North Carolina at Chapel Hill, and the National Health Sciences Research Committee of Malawi were followed. After agreeing to participate, each eligible child and the child's guardian were presented with an informed consent/assent in either English or Chichewa (the national language for Malawi). A parental consent was signed by at least one parent or guardian and those children older than 7 years and literate were provided an assent form. Each participant was then randomized to one of six dosing sequences that included three dosing formulations in a cross-over fashion with no washout period using a random number generator (PROC PLAN, SAS version 9.1; SAS Institute, Inc., Cary, NC, USA). The dosing formulations were GT, GL or TL given twice daily. The GT formulation was Triomune 40™, containing 40 mg d4T, 150 mg 3TC and 200 mg NVP (Cipla, Ltd; batch numbers K40227 and 646374). GL formulations were d4T (Stavir powder for oral solution 5 mg/ml, Government Pharmaceutical Organization, Ratchathewi, Bangkok, Thailand), 3TC (Lamivir oral solution 50 mg/5 ml; Cipla, Ltd), and NVP (nevimune oral suspension 50 mg/5 ml; Cipla, Ltd). TL formulations were d4T (Zerit powder for oral solution 1 mg/ml; Bristol-Meyers Squibb, Princeton, NJ, USA), 3TC (Epivir oral solution 10 mg/ml, GlaxoSmithKline; Research Triangle Park, NC, USA) and NVP (Viramune oral suspension 50 mg/5 ml; Boehringer Ingelheim, Columbus, OH, USA).
GT dosing was based on the Malawi paediatric dosing guidelines, which use quartered tablet multiples of Triomune 40™ according to patients' weight [7] . Because Triomune 40™ is a fixed-dose combination, quartered multiple dosing was based on an approximation of a mg/ kg daily dose of all three antiretrovirals. This approach lends to underdosing in some patients and overdosing in others when using quartered multiples of a fixed-dose combination. The GL dose was an equivalent mg/day dose to the GT dosing, whereas the TL dose was based on DHHS paediatric treatment guidelines from June 2003 ( Table 1 ) [8] . Current recommendations for NVP dosing are based on body surface area (mg/m 2 ); however, at the time of study initiation (2003) weightbased dosing (mg/kg) was the standard of care [8] . Each dosing formulation was given for 10-14 days with subsequent pharmacokinetic sampling over 6 h within a dosing interval. A washout period was not implemented, as these patients required continuous antiretroviral therapy for treatment of HIV. Patients and their guardians were given instructions on taking the medications and diaries to document dosing times. Pill counts and/ or liquid weights were used to assess adherence at each visit. As overnight visits could not be accommodated, an abbreviated 6 h pharmacokinetic visit followed a morning dose. Participants reported to the UNC Project building in the morning prior to their dose and 10-11 h after their previous evening dose. An intravenous catheter was placed and normal saline was administered to keep the line patent. A 5 ml whole blood sample was drawn just prior to their morning dose of medications (t=0 h). Subsequent samples were obtained at 1, 2, 4 and 6 h after the witnessed morning doses. Patients received breast milk and/or food within 1 h after the dose and lunch after the 4 h blood sample. Breakfast and lunch selections were similar for all subjects.
All whole blood samples were collected in K3 containing Vacutainer tubes (Fisher Scientific, Hampton, NH, USA) and centrifuged at 1,300×g at 4°C for 10 min. Plasma was removed and aliquoted to 2 ml cryovials and stored at -70°C until shipment to the UNC Center for AIDS Research Clinical Pharmacology and Analytical Chemistry lab for analysis.
Drug concentrations for d4T, 3TC and NVP were analysed using a validated HPLC-UV method that has been published previously [9] . Briefly, all three drugs and a hexobarbital internal standard were extracted from 500 µl of plasma using solid-phase extraction columns (BOND ELUT-C18; Varian, Inc., Harbor City, CA, USA) and 100% methanol as an eluent. Samples were dried under nitrogen steam and reconstituted in 100 ml of buffer. Each sample was injected onto an Agilent HP1100 system (Hewlett-Packard, Palo Alto, CA, USA) and analytes eluted using reverse-phase chromatography with a Waters Atlantis dC C-18 (3.9 mm×150 mm; 5 µm particle size) analytical column (Waters, Milford, MA, USA). Peaks were detected using UV absorbance and data collected using Chemstation software (Agilent, Santa Clara, CA, USA). The concentration range was 10-10,000 ng/ ml, with intra-and interday precision of 0.5-5.1% and accuracy of 0.5-5.6% for all concentrations. The laboratory participates in two external proficiency testing programmes: the AIDS Clinical Trials Group and the Dutch Association for Quality Assessment in TDM and Clinical Toxicology (KKGT International and Interlaboratory QC Program).
Non-compartmental methods were employed to calculate pharmacokinetic parameters using WinNonlin Pro 4.0.1 (Pharsight Corp, Mountain View, CA, USA). The 12-h plasma concentration (C 12 h ) was obtained using λ z extrapolations. Area under the curve (AUC) 0-6 h was calculated using the linear trapezoidal rule up to, and log trapezoidal rule after C max . C max and time to C max (T max ) were both determined by directly observing the data. Medians and ranges were calculated for all demographic and baseline data. Geometric means (90% confidence intervals [CIs] ) and geometric . The trough concentrations were extrapolated using C 0 h,ss =C/e -kt (where C is the predose concentration on day of pharmacokinetic study visit, k is the elimination rate and t is the difference in time after previous dose and 12 h). Adherence rates were determined on the basis of liquid measurements, pill counts or unit dose powder counts (for d4T) at each visit. Sample size was calculated using mean (±sd) for both C max and AUC 0-24 h for NVP. The most conservative sample size was determined to be 15 using a single-group repeated measures analysis of variance with a 0.05 significance level with 80% power to detect a 30% difference in means across the three levels of the repeated measures factor characterized by an effect size of 0.2570 (based on C max for NVP). A sufficient sample size of 18 participants was chosen.
Results
From a total of 24 screened patients, 18 HIV-infected children were enrolled and completed the study. Six patients were enrolled into each weight-based dosing group. Demographics for each dosing group are presented in Table 2 . Each child had been taking Triomune 40™ for a median (range) of 3.5 months (1-26) at the time of randomization. During the 30-day study period, patients had >98% adherence to study medications as assessed by diary cards, pill counts and liquid volume estimates.
All dosing groups
Descriptive statistics for the pharmacokinetic parameters of 3TC, d4T and NVP for all 18 participants are presented in Table 3 . Figure 1A , 1B and 1C are graphical representations of these data. Geometric mean ratios (90% CI) are presented for all formulation comparisons in Table 4 . Overall, for all dosing groups there were no significant differences in AUC 0-6 h , C max or C 0 h,ss for d4T, 3TC or NVP between formulations. Differences were only found for d4T and 3TC T max . Generally, the time to maximum concentration was delayed for d4T and 3TC for the GT formulation as compared to GL and TL, with the delay most significant in smaller children.
Individual dosing groups
Lamivudine
In examining the weight-based dosing groups separately, significant differences in pharmacokinetic parameters were found between the formulations. For group 1, GT AUC 0-6 h and C max were approximately 36-58% lower than GL and TL exposures. Conversely for group 2, GT AUC 0-6 h and C max were 36-46% higher compared with GL and TL. Additionally, the T max was delayed by 33-70% for the GT formulation compared with GL and TL for both groups 1 and 2. No clinically significant differences between the formulations were seen in group 3.
Stavudine
For group 1, AUC 0-6 h and C max were up to 61% higher for GT compared with GL and TL. For group 3, d4T exposure only was 29-45% lower with the GT compared with GL and TL. T max was 0.15-2.68 h longer for GT compared with both GL and TL for all groups, whereas GL was 0.20-0.83 h shorter than TL for all groups. No clinically significant differences between the formulations were seen in group 2.
Nevirapine
The least amount of variability in drug exposure between the formulations was seen for NVP. For group 1, GT and GL AUC 0-6 h and C max were 28-36% lower compared with TL. A total of 10 of 13 (77%) episodes of subtherapeutic (<3,000 ng/ml) concentrations were seen in this group, with 80% occurring during the GT and GL formulation phases. The current recommendation for NVP dosing is 300 mg/m 2 . Calculated this way, the median (range) dose of NVP in the GT/GL and TL groups was 251 mg/m 2 (177-304) and 285 mg/m 2 (204-356) with 2/18 (11%) patients in the GT/GL groups and 7/18 (39%) in the TL group with dosing >300 mg/m 2 . Overall, all formulations were well tolerated, and 10% of the children commented on the enjoyable taste of the liquid formulations. Over the study period, all patients either had a stable or decreasing HIV RNA (median [range] <400 copies/ml [261-2,837,779] at baseline and <400 copies/ml [49-38,546] at end of study).
Discussion
Antiretrovirals that are safe, effective and less expensive are crucial to the treatment of HIV in resource-poor countries such as Malawi where >12% of the population is infected, approximately 140,000 are receiving antiretrovirals and the annual Gross National Product is US $190 [3, 10] . Of those infected, approximately 10% are children <15 years old [11] . A total of 10% of infected children are taking antiretroviral therapy; however, this constitutes only one-half of the children in need of treatment who mostly rely on the government for their care [10] . The Malawi Ministry of Health guidelines, which was developed in 2003, provided for the use of quartered multiples of generic fixed-dose combinations for children, and provided children with access to these medications. Although splitting unscored fixed-dose combination tablets is not an optimal method of drug delivery, the guidelines for dosing Malawian children were thoughtfully developed on the basis of the availability of resources. This study provides pharmacokinetic data to support this practice for some, but not all, children. One study examining split dose GPO-VIR S30 (fixed-dose combination of d4T 30 mg, 3TC 150 mg and NVP 200 mg) in Thai children found only 1 of 34 children to have suboptimal NVP concentrations, with 12 of 13 children using this as their first-line antiretroviral regimen having undetectable viral loads [12] . However, previous pharmacokinetic evaluations by Ellis et al. [13] in African children using split tablets of Triomune 40™ have demonstrated that some do not achieve adequate NVP concentrations. Direct comparison of these studies cannot be performed, as two ethnically different populations were given two different generic fixed-dose formulations. The low NVP exposures in the Ellis et al. [13] study do, however, further support the suboptimal NVP exposures seen in 50% of our patients. Additionally, in both investigations in African children, the majority of patients with low NVP exposures were younger children. No studies to date have performed intrapatient comparisons for Triomune 40™ quartered tablets, individual generic and individual TL products. Therefore, this study aimed to evaluate the pharmacokinetics of 3TC, d4T and NVP in HIV-infected children receiving quartered multiples of Triomune 40™ as compared to the equivalent doses of the GL formulations and the National Institutes of Health recommended dose for children (at the time the study was conducted) using the US Food and Drug Administration approved trade products. Because little is known about the population differences in drug disposition, the latter comparison allowed us to evaluate exposures of drug from trade product in the Malawian population to Western cohorts.
The current investigation demonstrated that, for most children, the use of a split generic fixed-dose combination provided similar exposures to both GL and TL. This occurred despite the visible differences in size of each quarter tablet split with a commercial tablet splitter. Unpublished data from our laboratory determined that although Triomune 40™ had similar NVP content to Viramune tablets, it took longer to dissolve in an aqueous solution (25% less drug available at 6 h). Generally, 3TC exposures were lower for generic products as compared with trade formulations. This difference was driven by the consistently lower concentrations of 3TC in group 1 patients (8-<12 kg). Because of TL dosing being 11% higher than the generic dosing, this suggests underdosing of this group for 3TC. d4T results were highly variable, with patients in group 3 (28-<32 kg) having the lowest concentrations when given the GT formulation. Because the median dosing for all groups was similar (1.9, 2.1 and 2.1 mg/kg for groups 1, 2 and 3, respectively), this does not appear to be a phenomenon of underdosing.
Perhaps most concerning are the NVP data, where 10 of the 13 episodes of subtherapeutic NVP concentrations (<3,000 ng/ml) occurred in group 1. This difference is likely to the result of a suboptimal dosing strategy. Group 1 patients were given lower doses compared with groups 2 and 3. Comparing current dosing guidelines, children in group 1 were given a median (range) dose of 217 mg/m 2 (177-312) compared with children in groups 2 and 3 who were given NVP at 271 mg/m 2 (204-356) and 286 mg/m 2 (226-304), respectively. Overall, product source also appeared to affect drug exposure. Although the GL dosing strategy was 13% lower than the TL dosing strategy, exposures with this generic formulation were approximately 30% lower than with the trade formulation. We did not perform any testing on these formulations to determine whether differences in drug content could explain this finding.
This investigation also found some differences in the TL formulation exposures in Malawian children as compared to Western cohorts [14] [15] [16] . 3TC and d4T C max exposures with TL were both 39% lower in Malawians, whereas NVP exposures were 100% higher than that reported in Western cohorts [14] [15] [16] . Although this comparison was not an objective in this investigation, it does warrant discussion of the potential pharmacokinetic differences in these populations with consideration for safety and efficacy.
Because 3TC and d4T are readily absorbed, eliminated renally and have no liver metabolism, the reason for these differences in exposure is unclear . This might be the result of differences in age, weight, nutritional status or maturation of the gastrointestinal tract and/or renal system between the populations. The differences in NVP have been seen previously in an adult population, and might be the result of drug metabolism enzyme or transporter differences [6] . Studies are currently underway to assess what contribution P-glycoprotein and CYP450 polymorphisms might have on differences in NVP exposure in the Malawian population.
These data provide some support for the use of Triomune 40™ using these doses for children in groups 2 and 3 (18-<22 kg and 28-<32 kg). Based on the low concentrations of 3TC and NVP in children in group 1 (8-<12 kg), the investigators do not feel that dosing Triomune 40™ one-quarter tablet twice daily will provide adequate concentrations.
On the basis of these data and other investigations, the Malawi Ministry of Health changed the guidelines for treating HIV-infected children in 2006. Currently, it is recommended to use Triomune 30™ (30 mg d4T plus 150 mg 3TC plus 200 mg NVP) in lieu of the Triomune 40™ formulation [17] . Overall these new guidelines provide higher daily doses of each antiretroviral in children 8-<12 kg and avoid the underdosing that was found in this pharmacokinetic analysis. Additional generic paediatric formulations, such as Triomune Baby (6 mg d4T plus 30 mg 3TC plus 50 mg NVP) and Triomune Junior (12 mg d4T plus 60 mg 3TC plus 100 mg NVP), allow whole tablets to be administered to children [18] . The third edition of these guidelines, currently under evaluation in Malawi, might recommend use of these newer products and be the best alternative to liquid formulations. However, in children 18-<22 kg and 28-<32 kg, split dose Triomune 40™ is an appropriate alternative.
